Hyperperfusion on magnetic resonance imaging in acute chemotherapy-related leukoencephalopathy.
Acute chemotherapy-related leukoencephalopathy can present similar to acute stroke with symptoms including aphasia, dysarthria, and hemiplegia. Differentiation based on clinical appearance is challenging, and physicians must distinguish between the 2 conditions rapidly to institute appropriate therapies. An 8-year-old male with acute lymphoblastic leukemia receiving chemotherapy, including intrathecal methotrexate, presented to our emergency center with 2 hours of expressive aphasia and flaccid right hemiplegia. Emergent magnetic resonance imaging (MRI) was obtained, demonstrating diffusion restriction within bilateral corona radiata and centrum semiovale. Magnetic resonance perfusion revealed mildly increased perfusion, a finding inconsistent with ischemic stroke and previously unreported in acute chemotherapy-related leukoencephalopathy without necrosis. This increased perfusion conclusively eliminated stroke from the clinical differential. Magnetic resonance perfusion imaging proved valuable to rapidly distinguish acute chemotherapy-related leukoencephalopathy from ischemia, and the evaluation of perfusion alterations in this disorder may provide further insight into the pathophysiology of this entity.
El-Hakam
Lisa Michael
LM
Department of Pediatrics, Section of Pediatric Neurology and Developmental Neuroscience, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas 77030, USA. hakam@bcm.edu
Ramocki
Melissa Beth
MB
Riviello
James John
JJ
Illner
Anna
A
D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects; D002648:Child; D003561:Cytarabine / Q000009:adverse effects; D003937:Diagnosis, Differential; D006801:Humans; D056784:Leukoencephalopathies / Q000139:chemically induced* / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D020521:Stroke / Q000175:diagnosis; D014750:Vincristine / Q000009:adverse effects
D003561:Cytarabine; D011092:Polyethylene Glycols; D014750:Vincristine; C042705:pegaspargase; D001215:Asparaginase; D008727:Methotrexate